557 related articles for article (PubMed ID: 30362389)
1. Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes.
Polansky H; Javaherian A; Itzkovitz E
J Evid Based Integr Med; 2018; 23():2515690X18806269. PubMed ID: 30362389
[TBL] [Abstract][Full Text] [Related]
2. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir.
Polansky H; Javaherian A; Itzkovitz E
Drug Des Devel Ther; 2016; 10():2713-22. PubMed ID: 27621592
[TBL] [Abstract][Full Text] [Related]
3. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.
Polansky H; Itzkovitz E; Javaherian A
Clin Transl Med; 2016 Dec; 5(1):40. PubMed ID: 27766602
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus.
Polansky H; Itzkovitz E; Javaherian A
Drug Des Devel Ther; 2017; 11():575-583. PubMed ID: 28424535
[TBL] [Abstract][Full Text] [Related]
5. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
Polansky H; Lori G
J Evid Based Integr Med; 2020; 25():2515690X20932523. PubMed ID: 32551855
[TBL] [Abstract][Full Text] [Related]
6. Herpes Labialis: An Update.
Leung AKC; Barankin B
Recent Pat Inflamm Allergy Drug Discov; 2017; 11(2):107-113. PubMed ID: 28971780
[TBL] [Abstract][Full Text] [Related]
7. Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study.
Gilbert SC
J Drugs Dermatol; 2007 Apr; 6(4):400-5. PubMed ID: 17668537
[TBL] [Abstract][Full Text] [Related]
8. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
Abudalu M; Tyring S; Koltun W; Bodsworth N; Hamed K
Clin Infect Dis; 2008 Sep; 47(5):651-8. PubMed ID: 18637755
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies.
Baker D; Eisen D
Cutis; 2003 Mar; 71(3):239-42. PubMed ID: 12661753
[TBL] [Abstract][Full Text] [Related]
10. Oral antivirals for the acute treatment of recurrent herpes labialis.
Jensen LA; Hoehns JD; Squires CL
Ann Pharmacother; 2004 Apr; 38(4):705-9. PubMed ID: 14966254
[TBL] [Abstract][Full Text] [Related]
11. Expression of Concern to: Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.
Polansky H; Itzkovitz E; Javaherian A
Clin Transl Med; 2019 Feb; 8(1):5. PubMed ID: 30725243
[TBL] [Abstract][Full Text] [Related]
12. Valacyclovir for the treatment of genital herpes.
Brantley JS; Hicks L; Sra K; Tyring SK
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):367-76. PubMed ID: 16771614
[TBL] [Abstract][Full Text] [Related]
13. Single-dose famciclovir for the treatment of herpes labialis.
Hull C; Spruance S; Tyring S; Hamed K
Curr Med Res Opin; 2006 Sep; 22(9):1699-702. PubMed ID: 16968573
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks.
Lebrun-Vignes B; Bouzamondo A; Dupuy A; Guillaume JC; Lechat P; Chosidow O
J Am Acad Dermatol; 2007 Aug; 57(2):238-46. PubMed ID: 17416440
[TBL] [Abstract][Full Text] [Related]
15. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
16. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
17. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
[TBL] [Abstract][Full Text] [Related]
18. Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications.
Chacko M; Weinberg JM
Cutis; 2007 Jul; 80(1):77-81. PubMed ID: 17725069
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
Wald A; Selke S; Warren T; Aoki FY; Sacks S; Diaz-Mitoma F; Corey L
Sex Transm Dis; 2006 Sep; 33(9):529-33. PubMed ID: 16540883
[TBL] [Abstract][Full Text] [Related]
20. Recurrent herpes simplex labialis: selected therapeutic options.
Raborn GW; Grace MG
J Can Dent Assoc; 2003 Sep; 69(8):498-503. PubMed ID: 12954137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
